This whitepaper provides an analysis of the current market for biosimilars in the U.S. through interviews conducted with senior executives from specialty pharmaceutical manufacturing and distribution companies. In addition to stakeholder interviews, which reveal what will be necessary to create a more sustainable pathway for biosimilar introductions in the U.S., the report provides a brief regulatory history and information on FDA-approved biosimilars and the products in development.